American journal of clinical dermatology · 2020
Emerging Therapeutic Options for Chronic Pruritus.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reszke Radomir, Krajewski Piotr, Szepietowski Jacek C
Аннотация
Chronic pruritus, defined as an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks, is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to complex pathogenesis and profuse contributing factors, chronic pruritus therapy remains challenging. Regardless of the well-established antipruritic properties of classic pharmacotherapy (topical therapy, phototherapy and systemic therapy), these methods often provide insufficient relief for affected individuals. Owing to the growing interest in the field of pruritic research, further experimental and clinical data have emerged, continuously supporting the possibility of instigating novel therapeutic measures. This review covers the most relevant current modalities remaining under investigation that possess promising perspectives of approval in the near future, especially opioidergic drugs (mu-opioid antagonists and kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists and histamine H4 receptor antagonists.
Предметные рубрики MeSH
Analgesics, OpioidAntipruriticsBasic Helix-Loop-Helix ProteinsBiological FactorsChronic DiseaseClinical Trials as TopicHumansJanus Kinase InhibitorsNeurokinin-1 Receptor AntagonistsPhototherapyPruritusQuality of LifeReceptors, Aryl HydrocarbonReceptors, Histamine H4Receptors, Opioid, kappaReceptors, Opioid, muSkinTreatment Outcome